Japan has approved a subcutaneous autoinjector formulation of lecanemab (Leqembi Pen) for early Alzheimer's disease, allowing weekly 500 mg self-administration at home alongside the existing biweekly intravenous regimen. Approval drew on the 18-month Phase 3 Clarity AD core study and subcutaneous sub-studies in its extension, with the manufacturer reporting comparable drug exposure and a similar safety profile, including fewer systemic injection- or infusion-related reactions at 1.4%.
Key Points
- Weekly 500 mg subcutaneous dosing replaces biweekly infusion visits
- Systemic injection or infusion reactions reported in 1.4% of patients
- Home use pending insurance listing; first doses physician-supervised
Longevity Analysis
Anti-amyloid therapy depends on sustained administration over years, and the practical barrier has never been the molecule but the infusion schedule — clinic time, venous access, and the attrition that follows. Shifting delivery to a weekly injection a patient or care partner can perform at home converts an institutional protocol into a domestic routine, which is where adherence is actually won or lost. For cognitive preservation, where the therapeutic window sits early and the treatment horizon is long, removing friction from the delivery route may influence outcomes as much as the drug's pharmacology.
Original published by LT Wire.